Journal of Korean Medical Science

  • 제33권53호
  • /
  • Pages.342.1-342.6
  • /
  • 2018
  • /
  • 1011-8934(pISSN)
  • /
  • 1598-6357(eISSN)
대한의학회 (Korean Acad Medical Sciences)
권호 표지
DOI QR코드

DOI QR Code

Clinical Validation of a Protein Biomarker Panel for Non-Small Cell Lung Cancer

  • Jung, Young Ju (Department of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Oh, In-Jae (Department of Internal Medicine, Lung and Esophageal Cancer Clinic, Chonnam National University Hwasun Hospital) ;
  • Kim, Youndong (Aptamer Sciences Inc.) ;
  • Jung, Jong Ha (Aptamer Sciences Inc.) ;
  • Seok, Minkyoung (Aptamer Sciences Inc.) ;
  • Lee, Woochang (Department of Laboratory Medicine, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Park, Cheol Kyu (Department of Internal Medicine, Lung and Esophageal Cancer Clinic, Chonnam National University Hwasun Hospital) ;
  • Lim, Jung-Hwan (Department of Internal Medicine, Lung and Esophageal Cancer Clinic, Chonnam National University Hwasun Hospital) ;
  • Kim, Young-Chul (Department of Internal Medicine, Lung and Esophageal Cancer Clinic, Chonnam National University Hwasun Hospital) ;
  • Kim, Woo-Sung (Department of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Choi, Chang-Min (Department of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine)
  • 투고 : 2018.08.31
  • 심사 : 2018.10.09
  • 발행 : 2018.12.31
⟨ 이전 논문 다음 논문 ⟩

초록

We validated the diagnostic performance of a previously developed blood-based 7-protein biomarker panel, $AptoDetect^{TM}$-Lung (Aptamer Sciences Inc., Pohang, Korea) using modified aptamer-based proteomic technology for lung cancer detection. Non-small cell lung cancer (NSCLC), 200 patients and benign nodule controls, 200 participants were enrolled. In a high-risk population corresponding to ${\geq}55years$ of age and ${\geq}30pack-years$, the diagnostic performance was improved, showing 73.3% sensitivity and 90.5% specificity with an area under the curve of 0.88. $AptoDetect^{TM}$-Lung (Aptamer Sciences Inc.) offers the best validated performance to discriminate NSCLC from benign nodule controls in a high-risk population and could play a complementary role in lung cancer screening.

키워드

참고문헌

  1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016;66(1):7-30. https://doi.org/10.3322/caac.21332
  2. Jung KW, Won YJ, Kong HJ, Oh CM, Lee DH, Lee JS. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2011. Cancer Res Treat 2014;46(2):109-23. https://doi.org/10.4143/crt.2014.46.2.109
  3. National Lung Screening Trial Research Team; Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011;365(5):395-409. https://doi.org/10.1056/NEJMoa1102873
  4. National Lung Screening Trial Research Team; Church TR, Black WC, Aberle DR, Berg CD, Clingan KL, et al. Results of initial low-dose computed tomographic screening for lung cancer. N Engl J Med 2013;368(21):1980-91. https://doi.org/10.1056/NEJMoa1209120
  5. Moyer VA; U.S. Preventive Services Task Force. Screening for lung cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2014;160(5):330-8. https://doi.org/10.7326/M13-2771
  6. Birse CE, Tomic JL, Pass HI, Rom WN, Lagier RJ. Clinical validation of a blood-based classifier for diagnostic evaluation of asymptomatic individuals with pulmonary nodules. Clin Proteomics 2017;14(1):25. https://doi.org/10.1186/s12014-017-9158-9
  7. Brody EN, Gold L. Aptamers as therapeutic and diagnostic agents. J Biotechnol 2000;74(1):5-13.
  8. Kanwar JR, Roy K, Maremanda NG, Subramanian K, Veedu RN, Bawa R, et al. Nucleic acid-based aptamers: applications, development and clinical trials. Curr Med Chem 2015;22(21):2539-57. https://doi.org/10.2174/0929867322666150227144909
  9. Yuce M, Ullah N, Budak H. Trends in aptamer selection methods and applications. Analyst (Lond) 2015;140(16):5379-99. https://doi.org/10.1039/C5AN00954E
  10. Gold L, Ayers D, Bertino J, Bock C, Bock A, Brody EN, et al. Aptamer-based multiplexed proteomic technology for biomarker discovery. PLoS One 2010;5(12):e15004. https://doi.org/10.1371/journal.pone.0015004
  11. Ostroff RM, Bigbee WL, Franklin W, Gold L, Mehan M, Miller YE, et al. Unlocking biomarker discovery: large scale application of aptamer proteomic technology for early detection of lung cancer. PLoS One 2010;5(12):e15003. https://doi.org/10.1371/journal.pone.0015003
  12. Mehan MR, Williams SA, Siegfried JM, Bigbee WL, Weissfeld JL, Wilson DO, et al. Validation of a blood protein signature for non-small cell lung cancer. Clin Proteomics 2014;11(1):32. https://doi.org/10.1186/1559-0275-11-32
  13. Jung YJ, Katilius E, Ostroff RM, Kim Y, Seok M, Lee S, et al. Development of a protein biomarker panel to detect non-small-cell lung cancer in Korea. Clin Lung Cancer 2017;18(2):e99-107. https://doi.org/10.1016/j.cllc.2016.09.012
  14. Chong S, Lee KS, Chung MJ, Kim TS, Kim H, Kwon OJ, et al. Lung cancer screening with low-dose helical CT in Korea: experiences at the Samsung Medical Center. J Korean Med Sci 2005;20(3):402-8. https://doi.org/10.3346/jkms.2005.20.3.402
  15. Detterbeck FC, Mazzone PJ, Naidich DP, Bach PB. Screening for lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2013;143(5 Suppl):e78S-92S. https://doi.org/10.1378/chest.12-2350
  16. Smith MA, Battafarano RJ, Meyers BF, Zoole JB, Cooper JD, Patterson GA. Prevalence of benign disease in patients undergoing resection for suspected lung cancer. Ann Thorac Surg 2006;81(5):1824-8. https://doi.org/10.1016/j.athoracsur.2005.11.010
  17. Li XJ, Hayward C, Fong PY, Dominguez M, Hunsucker SW, Lee LW, et al. A blood-based proteomic classifier for the molecular characterization of pulmonary nodules. Sci Transl Med 2013;5(207):207ra142. https://doi.org/10.1126/scitranslmed.3007013
  18. Chapman CJ, Healey GF, Murray A, Boyle P, Robertson C, Peek LJ, et al. EarlyCDT(R)-Lung test: improved clinical utility through additional autoantibody assays. Tumour Biol 2012;33(5):1319-26. https://doi.org/10.1007/s13277-012-0379-2
  19. Pinsky PF, Church TR, Izmirlian G, Kramer BS. The National Lung Screening Trial: results stratified by demographics, smoking history, and lung cancer histology. Cancer 2013;119(22):3976-83. https://doi.org/10.1002/cncr.28326
  20. American College of Radiology. Lung CT screening reporting & data system (Lung-RADS). http://www.acr.org/Quality-Safety/Resources/LungRADS. Updated 2014. Accessed July 31, 2014.

피인용 문헌

  1. Clinical Application of Mass Spectrometry‐Based Proteomics in Lung Cancer Early Diagnosis vol.14, pp.5, 2020, https://doi.org/10.1002/prca.201900138
  2. Advances in Oligonucleotide Aptamers for NSCLC Targeting vol.21, pp.17, 2018, https://doi.org/10.3390/ijms21176075